BioForum – From Bench to Bedside: Advancing Radiopharmaceuticals in Victoria
August 14 @ 8:00 am - 11:00 am AEST
Event Navigation
Learn about the cutting-edge advancements in radiotherapies and radiopharmaceuticals and what this means for cancer diagnosis and treatment in Victoria.
Hear how innovators from Telix Pharmaceuticals, Peter Mac, and Cyclotek are manufacturing targeted radioisotopes for R&D, clinical trials and medical practice and changing the landscape of health care, and discover the opportunities and challenges in the radiopharmaceutical space.
Be informed about:
- Radiopharmaceuticals 101: Diagnostics, therapeutics and manufacturing
- Melbourne success stories – Telix Pharmaceuticals, Peter Mac, and Cyclotek
- Making it happen – Infrastructure, workforce training and logistics
- The future – New innovations and applications in clinical practice.
What to expect:
- The latest updates from industry experts
- Engaging information for diverse audiences
- Dynamic panel Q&A session
- In-person networking opportunities with peers.
Who should attend:
- Scientists and clinicians engaging in medical research, drug discovery programs and preclinical and clinical trials
- Health care providers, patient advocates and policy makers
- Professionals seeking to improve knowledge and foster connections.
Date: Wednesday 14 August 2024
Time (AEST):
7:45 am: Guest arrival and registration
8:00 am: Networking breakfast
9:00 am: Welcome and opening remarks
9:15 am: Presentations and Q&A
10:30 am: Networking
11:00: Close
Format: Hybrid – in person and live-streamed
Venue: Thornbury Room, Stamford Plaza Melbourne, 111 Little Collins Street, Melbourne Victoria 3000
Facilitator: Karen Parr, CEO, BioMelbourne Network
Speakers:
Samuel Graf, Innovation and Partnerships, Cyclotek
Dr Mo Haskali, Chief Radiopharmaceutical Scientist, Peter MacCallum Cancer Centre
Simone Leyden AM, Director Global Patient Advocacy and Government Affairs, Telix Pharmaceuticals
Host: Karen Parr, CEO, BioMelbourne Network
Registration:
In-person: Members $85; Non Members $175
Online: Members $25; Non Members $45
Unsure if your organisation is a member? Check our member directory
This event is kindly sponsored by the State Government of Victoria
Cancellation Policy
In-person registration:
Full refund given up to 7 days prior to the event
No refunds within 7 days of the event
Online registration:
Full refund given up to 3 days prior to the event
No refunds within 3 days of the event
Samuel Graf, Innovation and Partnerships, Cyclotek
Sam Graf is Head of Innovation and Partnerships at Cyclotek. Following the completion of his Master of Science at the University of Melbourne, Sam worked at the Peter MacCallum Cancer Centre as a Clinical Trial Coordinator. In 2022, Sam joined the team at Cyclotek to manage Cyclotek’s R&D projects and industry-academia collaborations.
Dr Mo Haskali, Chief Radiopharmaceutical Scientist, Peter MacCallum Cancer Centre
Dr. Haskali earned his PhD in radiopharmaceutical sciences from the University of Melbourne. His professional experience includes working at Cyclotek Pty. Ltd. (2013-2014), where he focused on radioactive drugs for disease diagnosis, including cancer. He then enhanced his expertise at the National Institute of Mental Health in the USA (2014-2016), developing radioactive drugs for PET imaging.
In 2016, Dr. Haskali joined the Peter MacCallum Cancer Centre (PMCC) as a senior radiopharmaceutical scientist. He was later appointed as PMCC's inaugural Chief Radiopharmaceutical Scientist, leading both clinical radiopharmaceutical provision and research on new radioactive drugs for clinical use.
Dr. Haskali is certified by the Australasian College of Physical Scientists and Engineers in Medicine (ACPSEM) as a radiopharmaceutical scientist. He currently serves on the ACPSEM's Professional Standards Board as the national representative for radiopharmaceutical sciences in Australia (2019-2023).
Notably, Dr. Haskali operates the world's largest hospital-based theranostic production facility and has established a nationally recognized training centre for theranostic production. His research group focuses on developing new radiolabelling methods for bioactive molecules, designing and synthesizing novel radiotracers and theranostics for PET imaging and radionuclide therapy, and providing clinical radiopharmaceuticals.
In 2016, Dr. Haskali joined the Peter MacCallum Cancer Centre (PMCC) as a senior radiopharmaceutical scientist. He was later appointed as PMCC's inaugural Chief Radiopharmaceutical Scientist, leading both clinical radiopharmaceutical provision and research on new radioactive drugs for clinical use.
Dr. Haskali is certified by the Australasian College of Physical Scientists and Engineers in Medicine (ACPSEM) as a radiopharmaceutical scientist. He currently serves on the ACPSEM's Professional Standards Board as the national representative for radiopharmaceutical sciences in Australia (2019-2023).
Notably, Dr. Haskali operates the world's largest hospital-based theranostic production facility and has established a nationally recognized training centre for theranostic production. His research group focuses on developing new radiolabelling methods for bioactive molecules, designing and synthesizing novel radiotracers and theranostics for PET imaging and radionuclide therapy, and providing clinical radiopharmaceuticals.
Simone Leyden AM, Director Global Patient Advocacy and Government Affairs, Telix Pharmaceuticals
https://www.linkedin.com/in/simone-leyden/
Karen Parr, CEO, BioMelbourne Network
Karen Parr brings almost 20 years’ experience in science policy, strategy, communications and engagement for government and industry bodies in Australia, New Zealand and the UK.
Karen is recognised for her ability to navigate complex stakeholder environments, forge trusted strategic partnerships and drive meaningful change within local, national and international environments.
She has worked extensively on public policy impacting life science companies, including opportunities and challenges traversing capital attraction, tax incentives, clinical trials, regulation and commercialisation of medical research. She established Australia’s Cell and Gene Catalyst and developed and launched research reports that resulted in increased global investment in Victoria and Australia.
Before joining BioMelbourne Network in June 2024, Karen was the Director of Policy and Communications at AusBiotech.
Karen is recognised for her ability to navigate complex stakeholder environments, forge trusted strategic partnerships and drive meaningful change within local, national and international environments.
She has worked extensively on public policy impacting life science companies, including opportunities and challenges traversing capital attraction, tax incentives, clinical trials, regulation and commercialisation of medical research. She established Australia’s Cell and Gene Catalyst and developed and launched research reports that resulted in increased global investment in Victoria and Australia.
Before joining BioMelbourne Network in June 2024, Karen was the Director of Policy and Communications at AusBiotech.
